# Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

> **NCT05136170** · PHASE3 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 85 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** Cenegermin
- **OTHER:** Vehicle

## Key facts

- **NCT ID:** NCT05136170
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-27
- **Primary completion:** 2023-05-24
- **Final completion:** 2023-05-24
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05136170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05136170, "Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05136170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*